Jane Street
CARM

Jane Street’s Carisma Therapeutics CARM Stock Holding History

Jane Street’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-33,210
Closed -$541K – 10326
2021
Q4 		$541K Sell
33,210
-615
-2% -$12.4K ﹤0.01% 7109
2021
Q3 		$537K Buy
33,825
+31,010
+1,102% +$1.49M ﹤0.01% 7148
2021
Q2 		$260K Buy
+2,815
New +$180K ﹤0.01% 8397

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return

Jane Street's CARM Position: Q3 2025 in Review

Jane Street sold out of Carisma Therapeutics (CARM) in Q3 2025, closing a stake of 150,810 shares — an estimated $59.1K sold.

Jane Street first reported a position in CARM in Q4 2018 and held it in 16 quarters. The position peaked at $1.29M in Q2 2021. 33 funds tracked by Wall St. Rank hold CARM as of Q3 2025.

  • Jane Street reported no remaining Carisma Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jane Street sold 150,810 Carisma Therapeutics shares in Q3 2025, an estimated $59.1K.
  • Jane Street first reported a position in Carisma Therapeutics in Q4 2018 and held it in 16 quarters.
  • Jane Street's Carisma Therapeutics position peaked at $1.29M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.